Information Provided By: 
Fly News Breaks for November 26, 2019
MDRX
Nov 26, 2019 | 05:11 EDT
UBS analyst Kevin Caliendo initiated coverage of Allscripts with a Neutral rating and $11.50 price target. Recent "lackluster" sales execution and a "less stable" client base than its larger peers makes it difficult to gain confidence in Allscripts achieving near-term growth at its three-year organic annual guidance of 3.5%-6.0%, Caliendo tell investors in a research note. The analyst finds it difficult to chart an upside pathway to consensus estimates.
News For MDRX From the Last 2 Days
There are no results for your query MDRX
